A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the best to prescribe upfront—and to which patients. Over the past 14 years, ...

When PSA rises after surgery, PSMA PET/CT detects cancer missed by conventional imaging ...

In a recent interview with CURE, Dr. Kai Tsao discussed treatment advancements for patients with prostate cancer. In a recent interview with CURE, Dr. Kai Tsao broke down current treatment ...

Please provide your email address to receive an email when new articles are posted on . Researchers at The Ohio State University have harnessed artificial intelligence machine learning processes to ...

In metastatic prostate cancer, AI-facilitated quantification of metastatic burden, accurate identification of castration resistance, and prediction of treatment sensitivity and resistance are active ...

In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC; Real‑world evidence showed Pluvicto achieved longer PFS when init ...

Approximately 20% to 30% of men with prostate cancer experience disease recurrence within 5 years of therapeutic intervention. 1 A key challenge in managing these patients is a scarcity of accurate ...

What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and providers in The Beam, published monthly.

Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for ...

When prostate cancer has spread beyond the prostate to nearby lymph nodes and other areas of the body and treatments can no longer slow or stop its growth, you are not alone. Many patients, despite ...